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Cell death is an important target for imaging the early response of tumors to treatment. 
We describe here validation of a phosphatidylserine-binding agent for detecting tumor 
cell death in vivo based on the C2A domain of Synaptotagmin-I. Methods: The 
capability of near infrared fluorophore-labeled and 99mTechnetium- and 111Indium-
labeled derivatives of C2Am for imaging tumor cell death, using planar near infrared 
fluorescence (NIRF) imaging and single photon computed tomography (SPECT) 
respectively, was evaluated in implanted and genetically engineered mouse models of 
lymphoma and in a human colorectal xenograft. Results: The fluorophore labeled 
C2Am derivative showed predominantly renal clearance and high specificity and 
sensitivity for detecting low levels of tumor cell death (2-5%). There was a significant 
correlation (R>0.9, P<0.05) between fluorescently-labeled C2Am binding and 
histological markers of cell death, including cleaved caspase-3, whereas there was no 
such correlation with a site-directed mutant of C2Am (iC2Am) that does not bind 
phosphatidylserine. 99mTc-C2Am and 111In-C2Am also showed favorable 
biodistribution profiles, with predominantly renal clearance and low non-specific 
retention in liver and spleen at 24 h after probe administration. 99mTc-C2Am and 
111In-C2Am generated tumor-to-muscle ratios in drug-treated tumors of 4.3× and 2.2× 
respectively at two hours and 7.3× and 4.1× respectively at twenty-four hours after 
administration. Conclusions: Given the favorable biodistribution profile of 99mTc- 
and 111In-labelled C2Am, and their ability to produce rapid and cell death-specific 










Detection of the early responses of tumors to therapy would allow rapid selection of 
the most effective treatment. Currently, clinical assessment of treatment response is 
based on Response Evaluation Criteria in Solid Tumors (RECIST), which define 
partial response as a reduction of at least 30% in the sum of the diameters of the target 
lesion (1). The problem for early detection of response is that these morphological 
changes may only occur weeks after the start of treatment and fail to detect response 
to cytostatic therapies (2).  
Cell death is an important target for imaging early treatment response (3), since 
most treatments induce tumor apoptosis and/or necrosis. However, there is as yet no 
reliable technique for routine imaging of cell death in the clinic (4). 
Phosphatidylserine, which is externalized on the outer leaflet of the plasma membrane 
bilayer in apoptosis, and is exposed through permeabilization of the plasma 
membrane in necrotic cells, can be detected using the 36-kDa phosphatidylserine–
binding protein, Annexin-V (AnxV) (5). 99mTc-labeled AnxV has been used to image 
drug-induced cell death in human tumors, including breast, lymphoma, lung (6) and 
head and neck squamous cell carcinoma (7). However, despite early promise, and the 
development of novel site-directed mutants of AnxV with improved biodistribution 
(8), problems with this agent persisted (9), including suboptimal pharmacokinetics 
and non-specific binding (10).  
We have developed a phosphatidylserine-targeted agent based on the C2A domain 
of Synaptotagmin-I. This was first used, in animal models, in the form of a dimeric 
glutathione S-transferase (GST)-tagged construct (84 kDa) for imaging tumor cell 
death using MRI (11,12) and, in 99mTc-labeled form, for imaging tumor cell death 
(13) and cardiac ischemia using SPECT (14), and, in 18F-labeled form, for imaging 
cell death in a rabbit lung cancer model using PET (15).  
More recently, we have used the isolated C2A domain, (16), which is much 
smaller (16 kDa), giving better tissue access and clearance, in which we have 
introduced a site-directed mutation (S78C; C2Am) that allows site-specific 
modification with an imaging label. Studies in vitro demonstrated that this probe 
showed a four-fold lower binding to viable cells and consequently improved 
specificity for detecting apoptosis and necrosis, when compared with AnxV (16).  
Moreover, removal of the GST tag, which is likely to be immunogenic, should 
facilitate translation of this agent to the clinic. 
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We have evaluated here the speed of detection, specificity, sensitivity and 
biodistribution profiles of AlexaFluor™750- and 99mTc- and 111In-labeled C2Am, for 
NIRF and SPECT imaging, respectively, of cell death in implanted models of 
lymphoma (EL4) (11) and colorectal cancer (Colo-205) (17), and in a spontaneous 
Myc-driven model of Burkitt’s lymphoma (Eμ-myc) (18). We also describe a site-
directed mutant of C2Am (iC2Am, D108N) that is inactive in phosphatidylserine 
binding, which we used to demonstrate that there were only low levels of non-specific 
probe retention. 
 
MATERIALS AND METHODS 
 
Probe expression and chemical labeling 
C2Am and iC2Am were expressed, purified and labeled using AlexaFluor™-750 
C5-maleimide, maleimide-HYNIC (for 99mTc) and maleimide-DOTA (for 111In) as 
described previously (16). Successful conjugation was confirmed using electrospray 
ionization mass spectrometry (ESI-MS) and radio HPLC (Supplemental Figs. 1-2). 
Phosphatidylserine binding activity of the conjugates was confirmed by surface 
plasmon resonance measurements (Supplemental Table 1). 
 
Cell culture  
EL4, murine lymphoma and Colo-205, human colorectal cells (ATCC) were 
cultured in RPMI medium (Life Technologies) containing 300 mg/L L-glutamine and 
10% (v/v) fetal bovine serum (FBS, PAA Laboratories).  Cell death was induced in 
EL4 cells by treatment with 15 µM etoposide (Pharmachemie BV) for 24 h at 37 °C. 
An automated analyzer (Vi-Cell™, Beckman Coulter) was used to monitor cell 
number and viability. 
 
Animals and tumor models 
EL4 or Colo-205 cells (>95% viability) were washed, re-suspended in chilled PBS, 
and implanted (5x106 cells) subcutaneously under isoflurane anesthesia, in the flank 
of C57BL/6 (BL6) or between the shoulder blades of BALB/c Nude (NU) mice (8-12 
week old females, from Charles Rivers Laboratories) respectively. Tumors were 
allowed to develop for between 8−13 days. Animals bearing EL4 tumors were treated 
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with 67 mg/kg body weight etoposide (i.p.), or solvent vehicle, at 24 h prior to 
imaging. BALB/c Nude mice bearing Colo-205 tumors were treated with 250 mg/kg 
body weight 5-fluorouracil (Sigma-Aldrich, 5-FU; i.p.) or solvent vehicle, at 24 h 
prior to imaging. Eμ-myc animals (Jackson Laboratories) were monitored daily and 
enrolled into the study when palpable lymph node masses were detectable (18). The 
mice were treated with 200 mg/kg body weight cyclophosphamide (Sigma-Aldrich; 
i.p.) 24−48 h prior to imaging.  
Biodistribution and NIRF imaging studies  
C2Am-AF750, iC2Am-AF750 or AnxV-750 (Annexin-Vivo™, Perkin Elmer) 
were administered at 0.10 μmol/kg (10 mL/kg, i.v.) to tumor-bearing NU mice. 
Imaging in vivo and/or ex vivo was performed using Li-Cor Pearl-Impulse™ or 
Xenogen IVIS200™ (Perkin Elmer) small animal imaging systems. Li-Cor Imaging 
Studio software (version 3.1.4) or Perkin Elmer Living Image (version 3.2) were used 
for image analysis.  
 
Biodistribution and SPECT studies 
Twenty-four hours after chemotherapy treatment, tumor-bearing mice received an 
injection (10 mL/kg, i.v.) of either 99mTc–C2Am (EL4 and Eμ-myc models) or 111In–
C2Am (Colo-205 model) at 7.5 nmol/kg (0.12 mg/kg, or ca. 1.5-2 MBq per mouse). 
SPECT studies were conducted in separate cohorts of mice 2 h after administration of 
radiolabelled C2Am at 75 nmol/kg, i.v., 1.2 mg/kg or ca. 15-20 MBq per mouse. 
Specific activities were 10-11.5 MBq/nmol for both 99mTc- and 111In-labeled C2Am. 
Injected doses were determined using a Dose Calibrator (ISO-MED 2000, MED 
Nuklear-Medizintechnik GmbH) and corrected for decay.  
 
Study approval 
All animal experiments were performed in compliance with a project license 
issued under the Animals (Scientific Procedures) Act of 1986 and were designed with 
reference to the UK Co-ordinating Committee on Cancer Research guidelines for the 
welfare of animals in experimental neoplasia (19).  Protocols were approved by the 
Cancer Research UK, Cambridge Institute Animal Welfare and Ethical Review Body. 





Preparation and characterization of imaging probes 
iC2Am-AF750 was produced by site-directed mutagenesis (D108N) of C2Am.  
This mutation abolishes binding to phosphatidylserine (20). C2Am and iC2Am were 
prepared and labeled with Alexa Fluor™-750 (C2Am-AF750, iC2Am-AF750), as 
described previously (16).  The proteins were fully modified, yielding a single 
molecular species on ESI-MS (Supplemental Fig. 1A-B). C2Am-AF750, C2Am-
HYNIC and C2Am-DOTA bound phosphatidylserine with similar affinities (Kd~60-
90 nM; Supplemental Table 1), as determined using surface plasmon resonance 
measurements (16). As expected, iC2Am-AF750 showed no binding.  C2Am was also 
modified stoichiometrically with maleimide-HYNIC or maleimide-DOTA, generating 
single species of MW 16426.5 Da, and 16749.8 Da, respectively, as determined by 
ESI-MS (Supplemental Fig. 1C-D). C2Am-HYNIC was loaded with 99mTc using 
methods described previously (21). C2Am-DOTA was loaded with 111InCl3 as 
described in Supplemental Methods. The conjugates were analyzed by HPLC 
(Supplemental Fig. 2). Radiolabeling efficiency was >94%.  
 
Fluorescence imaging of tumor cell death in vivo  
There was increased retention of C2Am-AF750 in drug-treated as compared to 
untreated EL4 (Fig. 1A, 2A), Colo-205 (Fig. 1B, 2B) and Eμ-myc tumors (Fig. 1C, 
2C) at 24 h after probe injection. Anx-AF750 showed no increase in retention 
following drug treatment in any of the tumor models. Although Anx-AF750 
fluorescence was greater than that of C2Am-AF750 in the EL4 tumor model this was 
not increased by drug treatment. The retention of iC2Am-AF750 in drug-treated 
tumors was less than of C2Am-AF750 in all of the tumor models and there was no 
significant difference in the retention of iC2Am-AF750 in untreated or treated Colo-
205 (Fig. 2B) and Eμ-myc tumors (Fig. 2C).  In drug-treated EL4 tumors there was an 
increase in tumor fluorescence in animals injected with iC2Am-AF750 (Fig. 2A), 
however the levels were 3× lower than with C2Am-AF750. This may be due to a 
treatment-induced increase in the enhanced permeability and retention (EPR) effect in 
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this tumor model (22). The heterogeneous skin pigmentation of Eμ-myc mice 
prevented accurate optical imaging in vivo and therefore for this tumor model 
fluorescence was measured ex vivo (Fig. 2C), which may explain the better contrast 
observed. All three tumor models showed a correlation between whole tumor mean 
C2Am-AF750 fluorescence intensities and CC3 staining of histological sections 
obtained post mortem (Fig. 2A-C, lower panels). This correlation was confirmed 
microscopically (Fig. 3). In Eμ-myc tumors C2Am-AF750 fluorescence was detected 
from regions where CC3 staining occupied as little as 1-2% of the ~1 mm2 regions of 
interest (Fig. 3C).  Differences in the relationship between fluorescence intensity and 
the levels of cleaved caspase-3 in the different tumors (Fig. 3) may reflect differences 
in phosphatidylserine exposure. 
 
Cell binding experiments with 99mTc-C2Am 
As we were unable to detect treatment response with AnxV-AF750, despite using 
the most recent agent and according to the manufacturer’s instructions, radionuclide 
imaging studies were performed solely with C2Am labeled with either 99mTc or 111In.  
There was a significant increase in the radioactivity retained by washed cell pellets 
prepared from suspensions of EL4 lymphoma cells that had been treated with 
etoposide (15 μM, for 24 h) and then incubated with 99mTc-C2Am in the 
concentration range of 1-100 nM (Fig. 4A).  Cell viability decreased from 95% to 
75% in these drug-treated cells, as assessed by trypan blue dye exclusion.  
 
Biodistribution  
99mTc-C2Am and 111In-C2Am showed favorable biodistribution profiles with 
predominantly renal clearance  (Table 1). 99mTc-C2Am had blood half-lives in EL4 
tumor-bearing animals of 7.2±0.6 h and 9.7±0.1 h in etoposide-treated and untreated 
animals, respectively. 111In-C2Am showed similar half-lives in Colo-205 tumor-
bearing animals of 11.4±1.2 h and 8.0±0.8 h in 5-FU-treated and untreated animals, 
respectively. Tumor-to-blood ratios increased progressively in chemotherapy-treated 
EL4 tumor-bearing animals, from 1.71±0.40 at 2 h to 6.96±1.08 at 24 h for 99mTc-
C2Am and from 1.38±0.65 at 2 h to 5.43±0.96 at 24 h for 111In-C2Am in Colo-205 
tumor-bearing animals. There was significantly greater retention in tumors and 
spleens (Fig. 4B, P<0.05) from etoposide-treated EL4 tumor-bearing animals, from as 
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early as 2 h following drug administration. The spleens showed significant increases 
in the levels of cell death following drug treatment (Supplemental Fig. 3).  
The biodistribution profiles of C2Am-AF750 and iC2Am-AF750 (Supplemental 
Table 2) were similar to those of 99mTc-C2Am and 111In-C2Am (Table 1).  As with 
99mTc-C2Am and 111In-C2Am, C2Am-AF750 generated EL4 tumor-to-muscle 
contrast from as early as 2 h (2.2±0.49) and up to 24 h (3.63±0.4) post injection of the 
imaging agent (Supplemental Table 2).  
 
SPECT imaging of tumor cell death in vivo using 99mTc-C2Am and 111In-C2Am 
Images were acquired from animals with implanted Colo-205 (Fig. 5A) tumors and 
from tumor-bearing Eμ-myc mice (Fig. 6A) prior to and 24 h after treatment with 5-
FU or cyclophosphamide, respectively, and 2 h after injection of 111In-C2Am or 
99mTc-C2Am, respectively. Corresponding studies with 99mTc-C2Am in etoposide-
treated EL4 tumors are shown in Supplemental Fig. 4. Maximum activity was 
observed in the kidneys and bladder, consistent with a predominantly renal excretion 
route (Table 1). Renal retention was mostly cortical (see Supplemental Fig. 4A). In 5-
FU-treated Colo-205 tumors (Fig. 5) 111In-C2Am uptake was increased by ~1.6× (Fig. 
5B, upper panel, P<0.05), reflecting a similar increase (1.65×) in the percentage of 
dead cells determined histologically in tumor sections (Fig. 5B, lower panel, P<0.05).  
In Eμ-myc mice, 99mTc-C2Am detected baseline levels of cell death in cervical tumors 
(Fig. 6A, left panel) and there was a ~1.9× increase (P<0.0001) in tumor signal post 
treatment (Fig. 6B, upper panel). Both cervical (Fig. 6A,  ) and axillary (Fig. 6A,  ) 
node tumors were clearly visible (Fig. 6A, arrow heads) following treatment (see 
Supplemental video 1). Histological analysis of tumor sections showed a similar 
increase in tumor cell death post treatment (~3×; P<0.05) (Fig. 6B, lower panel).  In 
EL4 tumors 99mTc-C2Am uptake increased post-treatment by ~1.3× (P<0.05), 
paralleling the modest increase and reflecting the wide variation in the levels of cell 
death in this tumor model (~1.6×; P<0.05). Treatment response was also observed in 
the spleen and salivary glands of these etoposide-treated animals (Supplemental Fig. 4 






Phosphatidylserine exposed by dying cells constitutes a temporally stable and 
abundant biomarker for detection of cell death (23).  We have been developing the 
C2Am domain of Synaptotagmin-I, which binds phosphatidylserine with nanomolar 
affinity, as a cell death imaging agent (16). Previous work with mouse lymphoma 
(EL4) and human triple-negative breast cancer (MDA-MB-231) cells demonstrated 
that C2Am has a higher specificity for binding to dead and dying cells in vitro, when 
compared with AnxV (16). We have demonstrated here, in vivo, that 99mTc-C2Am 
and 111In-C2Am have favorable biodistribution profiles with predominantly renal 
clearance (Table 1, Supplemental Fig. 4), and that C2Am was capable of detecting 
cell death in vivo with high sensitivity and specificity, in three mouse models, from as 
early as 2 h post administration.  
Binding of C2Am-AF750 was closely correlated with tumor cell death (Figs. 1−3), 
detecting cell death in regions with levels of CC3 staining as low as ~2% (Fig. 2B, 
lower panel; Figs. 3A & 3C, right panels). Although iC2Am-AF750 showed a small 
increase in uptake in EL4 tumors following treatment  (Fig. 2A, upper panel), this 
likely reflects an increased EPR effect following treatment (24). This effect was not 
observed in the other two tumor models, Eµ-myc and Colo-205 (Fig. 2B & 2C, upper 
panels), possibly due to lower levels of cell death in these models leading to better 
clearance of the probe from the tumor. 
 
111In-C2Am detected a treatment response in Colo-205 tumors within 2 h of probe 
administration, where the 60% increase in probe retention in treated tumors paralleled 
the increase in cell death determined histologically in tumor sections obtained post 
mortem, from 1.59±0.17% to 2.62±0.48% (Fig. 5B, P<0.05). In Eµ-myc tumors 
treatment resulted in a greater proportional increase in cell death (3×) and 
consequently a greater increase in 99mTc-C2Am retention (1.9×) (Fig. 6).  In EL4 
tumors, despite high levels of pre-existing cell death and a modest increase post 
treatment (1.6×) (Supplemental Fig. 4B), 99mTc-C2Am was nevertheless able to detect 
a significant treatment response (1.3× increase in probe retention, P<0.05, 
Supplemental Fig. 4B).  The capability of C2Am to detect small percentage increases 
in cell death suggests that C2Am should be capable of detecting treatment response in 
the clinic.  For example, levels of cell death can range from <2% prior to treatment to 
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5⎯15% post treatment (25).  These data also suggest that C2Am would be effective 
clinically in those tumors that show high levels of pre-existing cell death, such as non-
Hodgkin lymphoma, where high levels of spontaneous cell death (necrosis) have been 
reported in 25% of patients, frequently correlating with advanced disease and poor 
prognosis (26). Increased uptake of 99mTc-C2Am was also observed in the spleen and 
salivary glands of etoposide-treated animals (Fig. 4B, Supplemental Fig. 4A) and can 
be explained by etoposide-induced cell death in these tissues (27-28).  
 
Several imaging agents have been developed to detect tumor cell death, some of 
which have progressed to the clinic. Annexin-V (AnxV) binds phosphatidylserine 
with high affinity (5) and has been used widely as a preclinical tool for detecting cell 
death, both in vitro and in vivo. However, binding of AnxV to tumor tissue following 
therapy is thought not to be entirely phosphatidylserine-specific, possibly explaining 
the limited success of AnxV in the clinic, which has been hampered by high levels of 
non-specific binding to viable tissues, including the liver, gut and kidneys (29). 
Modifications to AnxV have shown limited improvements in biodistribution or 
contrast agent performance in vivo (8).  Duramycin is a 19-amino acid peptide that 
binds with high affinity and specificity to the phosphatidylethanolamine externalized 
by dying cells (30). 99mTc-labeled duramycin has been used recently to detect 
response to chemotherapy in a mouse model of colorectal cancer, where accumulation 
of the agent was found to correlate with markers of cell death (31). However, the 
clinical utility of duramycin has yet to be demonstrated.  Imaging agents that target 
cleaved and activated caspase-3 (CC3), an executioner caspase in the apoptosis 
pathway, have also been developed for detection of cell death in vivo (25) and a probe 
capable of detecting CC3 has progressed to clinical trials (32).  However, since CC3 
is a transient biomarker of cell death, the choice of temporal imaging window 
following treatment is critical (33). Furthermore CC3-targeted imaging agents are 
unable to identify caspase-independent modes of cell death, such as necrosis (34), 
which is often present following chemo or radiotherapy. 18F-ML-10, which appears to 
bind to dead cells by an unknown mechanism, has shown favorable safety and 
biodistribution profiles in humans (35). In a clinical study in ten patients with brain 
metastasis, there was enhanced retention (up to 2-fold) of 18F-ML-10 post 
radiotherapy and a good correlation between probe uptake and tumor size reduction 
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(36). However, there was no histological demonstration of increased cell death and 
the average reported decrease in tumor size post therapy was substantial (ca. 60% 
reduction). Therefore, the utility of 18F-ML-10 for detecting cell death in the most 
common clinical scenarios, in which therapy induces low levels of tumor cell death, 
has yet to be demonstrated.  
CONCLUSION  
We have demonstrated the capability of C2Am to detect tumor cell death in vivo as 
early as 2 h after administration. Radiolabelled C2Am derivatives showed favorable 
biodistribution profiles, with predominantly renal clearance and there was a close 
correlation between C2Am binding and histological markers of cell death. The 
capability of C2Am to detect relatively modest increases in cell death suggests that 
these agents will have sufficient sensitivity to detect tumor cell death in the clinic,  
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FIGURE 1. Near Infrared Fluorescence (NIRF) imaging of cell death. Imaging in 
vivo of untreated and treated EL4 (A), Colo-205 (B) and Eµ-myc (C) tumors.  Images 
are overlays of bright-field images and 800 nm-channel fluorescence signals, acquired 
24 h after C2Am-AF750 administration.  
 
FIGURE 2. NIRF imaging of cell death. Tumor mean fluorescence intensity (MFI) 
for untreated (open bars) and treated (filled bars) EL4 (A), Colo-205 (B) and Eµ-myc 
(C) tumors. Data for the Eµ-myc model was acquired ex vivo, due to skin 
pigmentation artifacts. Lower panels show correlation of C2Am whole tumor MFIs 
with corresponding cleaved caspase-3 (CC3) staining, measured in sections of excised 
EL4 (A), Colo-205 (B) and Eµ-myc (C) tumors. Drug-treated (open circles, 48 h post 
treatment) and untreated (filled circles). **P<0.01, ***P<0.001, n=3/group, values 
are mean ± SD. 
 
FIGURE 3. Maps of CC3 staining (left column), C2Am-AF750 fluorescence (middle 
column), and correlation (right column) of fluorescence intensities of regions of 
interest (ROIs; grids indicated in the left column), with staining for CC3 in the same 
ROIs. Tumors were excised 24 h after C2Am-AF750 administration and 48 h after 
drug treatment. The correlation coefficients (R) of the linear fits to the data (A-C, 
right column) are shown. Arrows in A (left column) indicate decellularized regions of 
tissue. Sections from EL4 (A), Colo-205 (B) and Eµ-myc (C) tumors. 
 
FIGURE 4.  (A) Binding of 99mTc-C2Am to EL4 cells. Labeling of drug-treated and 
untreated cells is expressed as a percentage of the total 99mTc activity retained by the 
cell pellets. **P<0.01, ***P<0.001, n=3/group, values are mean ± SD. (B) Retention 
of 99mTc-C2Am in tumors (top panel) and spleens (lower panel) from EL4 tumor-
bearing mice, in untreated ( ) and drug-treated () animals, at the indicated times 
after probe administration. Tissue retention is expressed as % of injected dose per 
gram of tissue (%ID/g of tissue). *P<0.05, n=3/group, 2-way analysis of variance, 
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with Bonferroni post-test correction, was used for group comparisons. Values are 
mean ± SD. 
 
FIGURE 5. SPECT imaging of cell death in vivo in Colo-205 tumors. Imaging of 
111In-labeled C2Am was performed 2 h after probe administration, and 24 h after drug 
treatment. (A) SPECT-CT fusion images of a representative untreated Colo-205 
tumor-bearing mouse (A, left panel) and a 5-FU treated animal (A, right panel), 2 h 
post administration of 111In-C2Am (A). Tumor location is indicated by the 
arrowheads.  (B) Tumor retention (% ID/mL) (upper panel) and CC3 staining (lower 
panel) in untreated and 5-FU-treated tumors. *P<0.05, n=3−4 tumors/group (B).  
 
FIGURE 6. SPECT imaging of cell death in vivo in Eµ-myc tumors. Imaging of 
99mTc-labeled C2Am was performed 2 h after probe administration, and 24 h after 
drug treatment. (A) SPECT-CT fusion images of representative Eµ-myc mice before 
(left) and after (right) cyclophosphamide treatment. Tumors in the neck, axillary 
region and chest cavity were visible (arrowheads, upper panel) and in axial sections 
across cervical ( , middle panel) and axillary ( , lower panel) planes. The red circles 
in (B) correspond to the %ID/mL retention values for tumors of the animals shown in 
(A). CC3 staining (B, lower panel) in untreated and drug-treated tumors. *P<0.05, 
***P<0.0001, n=6−7 tumors/group (A); n=6−13 tumors/group (B).  Abbreviations: 
BT, AT, before and after treatment, respectively. See Supplemental Data for statistical 





Table 1 – Biodistribution of 99mTc-C2Am in tumor-bearing EL4 mice (A) and of 
111In-C2Am in tumor-bearing Colo-205 mice (B), 24 h after etoposide and 5-FU 




Tissue 2 hours 24 hours 
(%ID/g) Mean SD Mean SD 
A     
Muscle 0.39 0.05 0.19 0.02 
Blood 1.02 0.08 0.20 0.01 
Tumor 1.74 0.39 1.41 0.21 
Spleen 3.30 0.47 2.34 0.29 
Liver 6.17 0.98 5.14 0.90 
Kidney 194.2 45.9 157.4 57.0 
Tumor-to-blood 1.71 0.40 6.96 1.08 
Tumor-to-muscle 4.5 1.15 7.3 1.40 
B Mean SD Mean SD 
Muscle 0.32 0.07 0.18 0.02 
Blood 0.50 0.22 0.13 0.02 
Tumour 0.69 0.09 0.72 0.10 
Spleen 0.92 0.17 1.18 0.20 
Liver 2.01 0.34 2.17 0.53 
Kidney 310 12 275 22 
Tumour-to-blood 1.38 0.65 5.43 0.96 
Tumour-to-
muscle 
2.16 0.48 4.09 0.88 
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